Medicus Pharma (NASDAQ:MDCX) Upgraded at Brookline Capital Management

Brookline Capital Management upgraded shares of Medicus Pharma ( NASDAQ:MDCX – Free Report ) to a strong-buy rating in a report issued on Monday, Zacks.com reports. Separately, Maxim Group began coverage on Medicus Pharma in a research note on Tuesday, December 17th.

They issued a “buy” rating and a $10.00 price objective on the stock. Get Our Latest Stock Report on MDCX Medicus Pharma Stock Performance Medicus Pharma Company Profile ( Get Free Report ) Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.



Medicus Pharma Ltd is based in Toronto, Ontario. Further Reading Five stocks we like better than Medicus Pharma When to Sell a Stock for Profit or Loss Top 3 Reasons to Invest in This Bond ETF for Stability and Growth What Are Earnings Reports? 2 Drone Stocks Surging from Increased Media Attention Market Cap Calculator: How to Calculate Market Cap Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter .

.